×
About 29,628 results

ALLMedicine™ Myeloma Center

Research & Reviews  14,233 results

Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute m...
https://doi.org/10.1111/ejh.13650
European Journal of Haematology; Jonsdottir G, Björkholm M et. al.

May 9th, 2021 - The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM). We identified all patients diagnosed with MM in Sweden from January 1st , 195...

A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel T...
https://doi.org/10.1016/j.clml.2021.03.006
Clinical Lymphoma, Myeloma & Leukemia; Mohyuddin GR, Hampton J et. al.

May 8th, 2021 - Lenalidomide use in nearly all induction regimens for multiple myeloma (MM) has led to the treatment of lenalidomide-refractory disease becoming one of the most important clinical questions in its treatment. Given the lack of direct comparisons of...

Co-evolution of tumor and immune cells during progression of multiple myeloma.
https://doi.org/10.1038/s41467-021-22804-x 10.1200/JCO.2005.04.242 10.1056/NEJMoa1411321 10.1016/S1470-2045(17)30578-8 10.1056/NEJMoa1506348 10.1016/S0140-6736(16)31594-X 10.1016/j.clml.2016.02.025 10.1038/ncomms3997 10.1200/JCO.2014.59.1503 10.1038/nature09837 10.1182/blood-2012-01-405985 10.1182/blood-2012-01-405977 10.1101/gr.191098.115 10.1038/nature09807 10.1126/science.1254257 10.1038/s41591-018-0269-2 10.1038/s41408-018-0160-x 10.1038/sj.leu.2402125 10.1038/sj.leu.2404304 10.1182/blood.V88.2.674.bloodjournal882674 10.1182/blood-2007-02-069625 10.1182/blood-2005-11-013458 10.1111/j.1365-2141.2004.04867.x 10.1155/2014/864058 10.1182/blood-2006-08-040410 10.1016/j.cell.2018.02.060 10.1038/nrclinonc.2016.122 10.1111/bjh.13256 10.1038/s41467-019-11591-1 10.1038/s43018-020-0053-3 10.1186/s12989-016-0129-5 10.1101/gad.180331.111 10.1101/gad.1874010 10.4049/jimmunol.1202736 10.3324/haematol.2010.025767 10.1093/nar/gkm525 10.1093/nar/gkp067 10.1016/S0092-8674(01)00611-0 10.1016/j.cellsig.2009.12.008 10.1182/blood-2006-07-038703 10.1111/j.1365-2141.2006.06325.x 10.1128/MCB.01187-07 10.1182/blood-2018-99-119941 10.1046/j.1365-2141.2003.04260.x 10.1038/nbt.3432 10.1038/nm.3733 10.18632/oncotarget.10850 10.1371/journal.pcbi.1003665 10.1093/annonc/mdx517 10.1186/s13059-015-0602-8 10.1177/147323001204000217 10.1158/0008-5472.CAN-08-2419 10.1093/bioinformatics/btaa403 10.1038/s41467-020-14743-w 10.1038/ncomms6210 10.1084/jem.20131831 10.1016/j.bbamcr.2009.07.009 10.1158/0008-5472.CAN-03-2516 10.3892/ijo.2013.2134 10.1111/bjh.13927 10.1182/bloodadvances.2017010801 10.1093/bioinformatics/bts271 10.1038/nbt.2514 10.1101/gr.129684.111 10.1093/bioinformatics/btp394 10.1093/nar/gkw491 10.1371/journal.pcbi.1004873 10.1093/bioinformatics/btv710 10.1101/gr.107524.110 10.1038/nature15393 10.1038/nbt.3519 10.1038/nbt.4096 10.1038/nmeth.4402 10.1126/science.1198704 10.1038/nature11247 10.1093/nar/gkx1081 10.1186/s12864-016-3195-z
Nature Communications; Liu R, Gao Q et. al.

May 8th, 2021 - Multiple myeloma (MM) is characterized by the uncontrolled proliferation of plasma cells. Despite recent treatment advances, it is still incurable as disease progression is not fully understood. To investigate MM and its immune environment, we app...

see more →

Guidelines  59 results

Mobilization and Exercise Intervention for Patients With Multiple Myeloma: Clinical Pra...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7781094
Physical Therapy; Jeevanantham D, Rajendran V et. al.

Sep 25th, 2020 - Individuals with multiple myeloma (MM) often have reduced functional performance due to the cancer itself or as a direct side effect of cancer treatments. Physical therapy is a part of cancer rehabilitation; however, no guidelines are available to...

Expert Perspective on ASCO20 Immunotherapy Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200234/full/

Jul 1st, 2020 - CAR T-cell therapy with BCMA-targeting idecabtagene-vicleucel (ide-cel) has emerged to be a game-changer as shown by this first pivotal phase II trial of CAR T-cell therapy in multiple myeloma (MM). Ide-cel is a first-in-class BCMA-directed CAR T-...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or interme...

Meletios A. Dimopoulos, MD, on Multiple Myeloma: Selinexor, Bortezomib, and Dexamethasone for Previously Treated Patients
https://ascopost.com/videos/asco20-virtual-scientific-program/meletios-dimopoulos-on-selinexor-bortezomib-and-dexamethasone-for-previously-treated-multiple-myeloma/

May 31st, 2020 - Meletios A. Dimopoulos, MD, of the University of Athens, discusses phase III results from the BOSTON trial, which showed that once-weekly selinexor, bortezomib, and dexamethasone significantly improved progression-free survival and overall respons...

First-in-Human Study Shows Favorable Activity With CC-92480 in Relapsed/Refractory Myeloma
https://www.targetedonc.com/view/first-in-human-study-shows-favorable-activity-with-cc-92480-in-relapsed-refractory-myeloma

May 29th, 2020 - Favorable activity and safety findings were demonstrated with the combination of CC-92480 plus dexamethasone as treatment of patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in an ongoing study, according to a presen...

see more →

Drugs  19 results see all →

Clinicaltrials.gov  14,447 results

Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute m...
https://doi.org/10.1111/ejh.13650
European Journal of Haematology; Jonsdottir G, Björkholm M et. al.

May 9th, 2021 - The aim of this study was to determine risk factors for development of acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) in patients with multiple myeloma (MM). We identified all patients diagnosed with MM in Sweden from January 1st , 195...

A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel T...
https://doi.org/10.1016/j.clml.2021.03.006
Clinical Lymphoma, Myeloma & Leukemia; Mohyuddin GR, Hampton J et. al.

May 8th, 2021 - Lenalidomide use in nearly all induction regimens for multiple myeloma (MM) has led to the treatment of lenalidomide-refractory disease becoming one of the most important clinical questions in its treatment. Given the lack of direct comparisons of...

Co-evolution of tumor and immune cells during progression of multiple myeloma.
https://doi.org/10.1038/s41467-021-22804-x 10.1200/JCO.2005.04.242 10.1056/NEJMoa1411321 10.1016/S1470-2045(17)30578-8 10.1056/NEJMoa1506348 10.1016/S0140-6736(16)31594-X 10.1016/j.clml.2016.02.025 10.1038/ncomms3997 10.1200/JCO.2014.59.1503 10.1038/nature09837 10.1182/blood-2012-01-405985 10.1182/blood-2012-01-405977 10.1101/gr.191098.115 10.1038/nature09807 10.1126/science.1254257 10.1038/s41591-018-0269-2 10.1038/s41408-018-0160-x 10.1038/sj.leu.2402125 10.1038/sj.leu.2404304 10.1182/blood.V88.2.674.bloodjournal882674 10.1182/blood-2007-02-069625 10.1182/blood-2005-11-013458 10.1111/j.1365-2141.2004.04867.x 10.1155/2014/864058 10.1182/blood-2006-08-040410 10.1016/j.cell.2018.02.060 10.1038/nrclinonc.2016.122 10.1111/bjh.13256 10.1038/s41467-019-11591-1 10.1038/s43018-020-0053-3 10.1186/s12989-016-0129-5 10.1101/gad.180331.111 10.1101/gad.1874010 10.4049/jimmunol.1202736 10.3324/haematol.2010.025767 10.1093/nar/gkm525 10.1093/nar/gkp067 10.1016/S0092-8674(01)00611-0 10.1016/j.cellsig.2009.12.008 10.1182/blood-2006-07-038703 10.1111/j.1365-2141.2006.06325.x 10.1128/MCB.01187-07 10.1182/blood-2018-99-119941 10.1046/j.1365-2141.2003.04260.x 10.1038/nbt.3432 10.1038/nm.3733 10.18632/oncotarget.10850 10.1371/journal.pcbi.1003665 10.1093/annonc/mdx517 10.1186/s13059-015-0602-8 10.1177/147323001204000217 10.1158/0008-5472.CAN-08-2419 10.1093/bioinformatics/btaa403 10.1038/s41467-020-14743-w 10.1038/ncomms6210 10.1084/jem.20131831 10.1016/j.bbamcr.2009.07.009 10.1158/0008-5472.CAN-03-2516 10.3892/ijo.2013.2134 10.1111/bjh.13927 10.1182/bloodadvances.2017010801 10.1093/bioinformatics/bts271 10.1038/nbt.2514 10.1101/gr.129684.111 10.1093/bioinformatics/btp394 10.1093/nar/gkw491 10.1371/journal.pcbi.1004873 10.1093/bioinformatics/btv710 10.1101/gr.107524.110 10.1038/nature15393 10.1038/nbt.3519 10.1038/nbt.4096 10.1038/nmeth.4402 10.1126/science.1198704 10.1038/nature11247 10.1093/nar/gkx1081 10.1186/s12864-016-3195-z
Nature Communications; Liu R, Gao Q et. al.

May 8th, 2021 - Multiple myeloma (MM) is characterized by the uncontrolled proliferation of plasma cells. Despite recent treatment advances, it is still incurable as disease progression is not fully understood. To investigate MM and its immune environment, we app...

see more →

News  851 results

Multiple Myeloma Clinical Practice Guidelines (EHA/ESMO, 2021)
https://reference.medscape.com/viewarticle/948408

Mar 31st, 2021 - Clinical guidelines on the management of multiple myeloma (MM) were published in February 2021 by the European Hematology Association and the European Society for Medical Oncology in HemaSphere.[1] Watchful waiting is recommended for patients with...

Assessing Measurable Residual Disease Tied to Better Outcome in Multiple Myeloma
https://www.medscape.com/viewarticle/943007

Dec 21st, 2020 - NEW YORK (Reuters Health) - Clinical decision-making based on assessment of measurable residual disease (MRD) is associated with better outcome in patients with multiple myeloma (MM), a real-world study indicates. Patients who were MRD negative, a...

Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma
https://www.medscape.com/viewarticle/942222

Dec 7th, 2020 - Data from the Apollo study provide proof for the subcutaneous administration (sc) of daratumumab (Darzalex Faspro) in combination with pomalidomide (Pomalyst) and dexamethasone (Pd) for patients with relapsed or refractory multiple myeloma (RRMM)....

Circulating miRNA for Early Diagnosis of Multiple Myeloma
https://www.medscape.com/viewarticle/941594

Nov 24th, 2020 - Circulating microRNAs (miRNAs) could be a potential noninvasive biomarker for early diagnosis of multiple myeloma (MM), according to the results of a meta-analysis published online in the Journal of Bone Oncology. In recent years, because of the r...

Venetoclax Boosts Progression-Free Survival in Myeloma Patients, but May Cause More Deaths
https://www.staging.medscape.com/viewarticle/940774

Nov 11th, 2020 - NEW YORK (Reuters Health) - The oral BCL-2 inhibitor venetoclax prolongs progression-free survival (PFS) in patients with relapsed or refractory multiple myeloma (MM), but at the cost of lower overall survival, a phase-3 trial suggests. In subset ...

see more →

Patient Education  19 results see all →